We investigated the effects of a 5-hydroxytryptamine (5-HT) 1A receptor gene polymorphism on the clinical response to fluvoxamine (FLV) in 65 depressed outpatients who gave written consent to participate in the study. Patients visited every 2 weeks after the first examination until the week 12 end point and were evaluated by the 17-item Hamilton Rating Scale for Depression (HAM-D-17) at each visit. FLV dose was changed in response to their clinical symptoms. The Gly272Asp polymorphism of the 5-HT1A receptor gene was identified by a PCR method. The subjects with the Asp allele had a significantly higher % reduction in the HAM-D-17 score than those with the Gly/Gly genotype at week 2 (P ¼ 0.009), week 6 (P ¼ 0.036), and week 12 (P ¼ 0.031). There was a significant difference in the genotype distribution between the responders and nonresponders. These results suggest that the Gly272Asp polymorphism of the 5-HT1A receptor gene may predict the response to FLV.
INTRODUCTION
Depression is one of the most common psychiatric diseases, with an incidence of about 4% and a life-time prevalence of 15-20%. 1, 2 Although a large number of antidepressants are available in the clinical situation, approximately 30% of patients fail to respond satisfactorily to the treatment administered. 3 Moreover, all antidepressant treatments require an administration of at least 2 weeks before inducing a clinically significant improvement. 4 Preclinical studies have indicated that the delayed action of serotonergic antidepressants is partly due to the existence of a negative feedback mechanism involving 5-hydroxytryptamine-1A (5-HT1A) autoreceptors. Most antidepressants, especially the selective serotonin reuptake inhibitors (SSRIs), increase the concentration of 5-HT present in the synaptic cleft. 5, 6 The increased levels of 5-HT will act on postsynaptic receptors as well as presynaptic receptors including 5-HT1A somatodendritic receptors, which exert negative feedback on the axon, reducing the release of new 5-HT into the cleft, and thereby reducing the effect of SSRI antidepressant medication. 7, 8 It has also been indicated that during treatment with SSRIs, synaptic concentrations of 5-HT do not increase until after the 5-HT1A receptors have been functionally desensitized. [9] [10] [11] [12] The delay in the onset of therapeutic benefits is thought to be caused by this process. Clinical trials based on these hypotheses have revealed that combination therapy with SSRIs and an 5-HT1A autoreceptor antagonist increased the therapeutic efficacy in depressive patients. 13, 14 On the other hand, a number of polymorphisms have been identified in the human 5-HT1A receptor gene and some of the genetic variations alter the extracellular aminoterminal domain of the 5-HT1A receptor. 15 Several 5-HT1A receptor gene variants have been detected to date in Caucasian populations, but their frequencies are very low in the Japanese population. [15] [16] [17] Recently, Kawanishi et al 17 detected a new structural polymorphism, Gly272Asp, in the Japanese population. The effect of this polymorphism on the function of 5-HT1A is unclear, and to the best of our knowledge, there have been no studies investigating the effect of this polymorphism on the response to SSRIs.
In this study, we investigated the effect of the Gly272Asp polymorphism of the 5-HT1A receptor gene on the clinical response to fluvoxamine (FLV).
RESULTS
Among the 65 patients, 10 patients with the Gly/Gly genotype could not complete the 12-week study due to side effects or for unknown reasons. The genotypes of three patients could not be identified. Genetic variation was in the Hardy-Weinberg equilibrium. The genotype frequencies, as well as the clinical and demographic characteristics of the sample, are shown in Table 1 . Since the Asp/Asp genotype group contained only one sample, the analysis was performed between the subjects with the Gly/Gly genotype and those with the Gly/Asp or Asp/Asp genotypes. No significant differences were demonstrated for age and sex between the two genotype groups. There were also no significant differences between the two genotype groups for the baseline 17-item Hamilton Rating Scale for Depression (HAM-D-17) scores. Figure 1 There was a significant difference in the genotype distribution between the responders and nonresponders, while the percentages of remitters were similar among the genotype groups (Table 1) .
DISCUSSION
The frequencies of the Gly/Gly, Gly/Asp and Asp/Asp genotypes were 87, 11, and 2%, respectively. There are only two previous studies that have reported the distribution of the Gly272Asp polymorphism of the 5-HT1A receptor gene in the Japanese population. Kawanishi et al 17, 18 reported that the genotype frequencies of Gly/Gly, Gly/Asp, and Asp/ Asp were 95, 5, and 0% and Nishiguchi et al reported 91, 8, and 1%, respectively. The genotype frequencies observed in this study are consistent with these previous studies.
Our results show a significant effect of the Gly272Asp polymorphism of the 5-HT1A receptor gene on the clinical response to FLV, and to our knowledge, this is the first study reporting a relationship between the 5-HT1A receptor gene polymorphism and the antidepressant response. The subjects with the Gly/Asp or Asp/Asp genotypes had a significantly higher % reduction in the HAM-D-17 score at weeks 2, 6, and 12, and there was a particularly large difference in the % change in the HAM-D-17 score between the Gly/Gly genotype group and the Gly/Asp or Asp/Asp genotype group at week 2. At week 2, the Gly/Asp or Asp/ Asp group had a 53.5% reduction in the HAM-D-17 score, while the other group had only a 26.3% reduction. This result suggests that the 5-HT1A receptor gene polymorphism might affect the initial response to FLV. There are several studies that have indicated that the delay in the onset of the 4, [9] [10] [11] [12] Our results appear to be consistent with these previous findings.
It is supposed that 5-HT1A receptor antagonists can cancel the delay in the onset of the therapeutic effects of antidepressants. A more rapid onset of action of SSRIs has been reported to be induced by 5-HT1A antagonists, such as pindolol, in recent studies. Tome et al 19 reported a significant acceleration in the onset of the effect of paroxetine observable from day 4 in a group receiving pindolol. It has been also indicated that a greater number of patients showed improvement in the pindolol plus paroxetine group than in the placebo plus paroxetine group at day 10. 13 Perez et al 20 reported that the number of days required to reach a sustained response was lower in the fluoxetine and pindolol group than in the fluoxetine and placebo group. These clinical findings also show that 5-HT1A receptors play an important role in the delay of the onset of the therapeutic effect.
Although the therapeutic finding has not been consistently regulated, if the Gly/Asp or Asp/Asp genotypes accelerate the initial response to SSRIs, SSRIs-pindolol augmentation therapy should be chosen for subjects with the Gly/Gly genotype from the start of the medication. Therefore, it may be possible to select the most suitable medication for the treatment of depression based on a genetic factor.
Furthermore, it was observed that the subjects with the Asp allele also showed a greater % reduction in the HAM-D-17 score at week 12. This result may suggest that the more rapid onset of the action of FLV is correlated with a superior outcome at week 12. In the study by Tome et al, 19 patients who were originally treated with pindolol showed a better outcome at week 24 than patients taking paroxetine alone. In the study by Perez et al, 20 the difference between pindolol and placebo administrations in the cumulative percentages of patients with a sustained response was maintained until the end of the 6-week period. Although these preceding studies have shown a significant effect of the more rapid onset of action of SSRIs on a prolonged response, the function of the 5-HT1A receptor gene polymorphism remains unclear and needs to be discussed.
In this study, the only patient with the Asp/Asp genotype showed a 75% reduction in the HAM-D-17 score at week 2, and the HAM-D-17 score changed from 28 points at week 0 to 7 points at week 2. None of the subjects with the Gly/Asp genotype showed a greater % reduction in the HAM-D-17 score than the subject with the Asp/Asp genotype. Although it is impossible to clarify the differences in the response to FLV between the Gly/Asp and Asp/Asp genotypes because there was only one patient with the Asp/Asp genotype in this study, this finding suggests the possibility that subjects with the Asp/Asp genotype may have a better response to FLV than subjects with the Gly/Asp or Gly/Gly genotypes.
The Gly272Asp mutation was recently identified in the Japanese population. Although Kawanishi et al 17 expected that this substitution might alter the signal transduction function through G-protein coupling, the function of the amino-acid change is still unclear. Several other mutations of the 5-HT1A receptor gene have been detected in previous studies, but their functions also remain unclear. Therefore, the effects of these other mutations on the clinical response to FLV cannot be excluded. Furthermore, although the subjects who are diagnosed with major depressive disorder should be enrolled in this study, the sample is not homogeneous as for diagnosis. It is supposed that this heterogeneity of diagnosis affects the response to FLV. However, since all subjects with Asp allele are diagnosed with major depressive disorder, the effect of different diagnosis on our result may be not so great.
There is a limitation within our results that the frequency of this mutation in Caucasian samples has not been studied to date. If the frequency is very low, our results will not be useful for Caucasian patients.
It was demonstrated that patients with the Asp allele had a more rapid onset of the action of FLV, and that their final response rate to FLV was also greater than that of patients without the Asp allele. However, this study has the limitation of a small sample size and much research remains to be done to explain the mechanism. Further studies are needed to clarify the effect of the 5-HT1A receptor gene polymorphism on the clinical response to SSRIs.
MATERIALS AND METHODS

Subjects
This study was conducted at the Niigata University Medical Hospital. The study protocol was approved by the Ethics Committee of Niigata University Medical Hospital, and each subject provided written informed consent before enrolment. The subjects were 65 Japanese depressed outpatients (34 males, 31 females), and their mean age7SD was 40.5714.0 years. In all, 58 subjects had DSM-IV diagnoses of major depressive disorder, three had adjustment disorder with depressed mood, and four had a depressive disorder not otherwise specified. The exclusion criteria were additional diagnoses on Axis I or Axis II of the DSM-IV. All the patients were free from psychotropic drugs for at least 14 days before their entry into the present study. Demographic data, medical histories, and laboratory data, including hematology, serology, electrolytes, and urine analysis, were collected for each patient. Patients with obvious physical illnesses were excluded from the present study. All patients were orally treated with FLV for their psychiatric illnesses.
Study Design
On the first examination (week 0), after the patients had given their informed consent, their symptoms were evaluated by HAM-D-17 and they were treated with FLV at a starting dose of 25 mg/day for the first week. The patients visited at weeks 1, 2, 4, 6, 8, 10, and 12 after the first examination. The HAM-D-17 score and side effects were assessed at each visit. If the improvement rate in the HAM-D-17 score was less than 40% in comparison to the score on the last visit, the FLV dose was increased from 25 mg/day to 50, 100, 150, and 200 mg/day after that. When the patients 
Data Collection
Blood sampling was performed using a Venoject s tube containing EDTA-Na (Terumo Japan, Tokyo, Japan) at week 1. In all, 7 ml of venous blood was collected, and genomic DNA was extracted from the samples within 2 h of collection. The target mutation of the 5-HT1A receptor gene was characterized by a single base-pair substitution (815G-A) at the position of codon 272 that resulted in an amino-acid exchange (Gly272 to Asp). To detect this mutation, polymerase chain reaction (PCR) was performed with the following primers: 5 0 GGAGCTTTCTACATCCCGCTG 3 0 -5 0 CTGGCGGCAGAACTTACACTT 3 0 . The amplification was carried out in a 10 ml volume containing 50 ng genomic DNA, 2 pmol of each primer, 1 ml 10 Â Ex Taq buffer, 0.8 ml dNTP mixture, and 0.25 U of Ex Taq (Takara Biomedicals, Tokyo, Japan). After an initial 4 min denaturation at 941C, 40 cycles of denaturing at 941C for 30 s, annealing at 601C for 30 s, and extension at 721C for 1 min were conducted, followed by a final extension step at 721C for 4 min, using a thermal cycler. The PCR products were refined and the target mutation of the 5-HT1A receptor gene was identified using a MegaBASE Single Nucleotide Primer Extension (SNuPe) Genotyping kit (Amersham Biosciences, USA).
Statistical Analysis
The clinical and demographic characteristics were compared between groups with unpaired t-tests or Fisher's exact tests. Comparisons of the time courses of the HAM-D-17 scores were performed using a two-way repeated-measures analysis of variance, with time (week) as a within-subjects factor, and genotype as a between-subjects factor. The genotype distributions were analyzed using Fisher's exact test. The level of significance was set at less than 0.05.
